Soriatane and Alcohol/Food Interactions

CONTRAINDICATED: Ethanol consumption with acitretin leads to the formation of etretinate, which has a much longer half-life than acitretin. Major human fetal abnormalities have been associated with the administration of acitretin, etretinate, and other retinoids. The longer elimination half-life of etretinate relative to acitretin increases the duration of teratogenic potential for female patients. In one case report of a patient with apparent sporadic ethanol intake, etretinate was present in plasma and fat for 52 months after acitretin was discontinued.

MANAGEMENT: Female patients should be warned that ethanol is contraindicated during active treatment with acitretin and for two months after cessation of therapy.

Switch to consumer interaction data

CONTRAINDICATED: Ethanol consumption with acitretin leads to the formation of etretinate, which has a much longer half-life than acitretin. Major human fetal abnormalities have been associated with the administration of acitretin, etretinate, and other retinoids. The longer elimination half-life of etretinate relative to acitretin increases the duration of teratogenic potential for female patients. In one case report of a patient with apparent sporadic ethanol intake, etretinate was present in plasma and fat for 52 months after acitretin was discontinued.

MANAGEMENT: Female patients should be warned that ethanol is contraindicated during active treatment with acitretin and for two months after cessation of therapy.

Switch to consumer interaction data

acitretin - hyperlipidemia

Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values. It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established. Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions. Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin. Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.

acitretin - hyperlipidemia

Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values. It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established. Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions. Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin. Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.